EMC announced Documentum Submission, Store and View, for simplified storage, search, and retrieval of submission documentation and all associated correspondence...
As part of the EMC Documentum for Life Sciences Solution Suite, EMC announced Documentum Submission, Store and View (SSV), for simplified storage, search and retrieval of submission documentation and all associated correspondence, which adheres to security and compliance regulations.
Documentum SSV links regulatory correspondence and communications to submission files, enabling a 360-degree view of regulatory activity. It also automatically stores electronic common technical documents (eCTD), non-eCTD electronic submissions (NeeS) and paper submissions into a scalable Documentum repository that delivers advanced security, audit trail, metadata and indexing capabilities.
In a conversation with Applied Clinical Trials, Lori McKellar, Director, Market Development, and Steve Scribner, Principal Consultant, both with Life Sciences at EMC, told us that the solution can be hosted or on-premise and offers leveled access controls for the sponsor and their affiliated regulatory representatives. Further, Scribner explained the need for a full-view of the regulatory communications as sponsors simultaneously file multiple submissions to different global regulatory authorities, primarily through local affiliates, a contracted service. “The sponsors and CROs need this local expertise. Submissions aren’t the same for each country and the affiliate carries on that level of detail,” said Scribner. The danger is that the agency will communicate to an affiliate, and that information will be misunderstood or not make it in a timely fashion to the sponsor.
More specifically, EMC Documentum SSV enables:
Read the full release on their blog here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.